These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 28806666)

  • 21. Synergistic antitumor effect of folate-targeted Pluronic™ F-127/poly(lactic acid) polymersomes for codelivery of doxorubicin and paclitaxel.
    Wu TY; Li ZL; Gong YC; Xiong XY
    Nanomedicine (Lond); 2023 Feb; 18(5):455-469. PubMed ID: 37166001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-delivery of paclitaxel and doxorubicin using polypeptide-engineered nanogels for combination therapy of tumor.
    Yang J; Jin RM; Wang SY; Xie XT; Hu W; Tang HF; Liu B
    Nanotechnology; 2022 Jan; 33(15):. PubMed ID: 34963110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation.
    Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X
    Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
    Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles.
    Kang MS; Singh RK; Kim TH; Kim JH; Patel KD; Kim HW
    Acta Biomater; 2017 Jun; 55():466-480. PubMed ID: 28373086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyaluronate tethered, "smart" multiwalled carbon nanotubes for tumor-targeted delivery of doxorubicin.
    Datir SR; Das M; Singh RP; Jain S
    Bioconjug Chem; 2012 Nov; 23(11):2201-13. PubMed ID: 23039830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined photodynamic-chemotherapy investigation of cancer cells using carbon quantum dot-based drug carrier system.
    Li X; Vinothini K; Ramesh T; Rajan M; Ramu A
    Drug Deliv; 2020 Dec; 27(1):791-804. PubMed ID: 32420760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular pH-responsive and rituximab-conjugated mesoporous silica nanoparticles for targeted drug delivery to lymphoma B cells.
    Zhou S; Wu D; Yin X; Jin X; Zhang X; Zheng S; Wang C; Liu Y
    J Exp Clin Cancer Res; 2017 Feb; 36(1):24. PubMed ID: 28166836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbon dots incorporated polymeric hydrogels as multifunctional platform for imaging and induction of apoptosis in lung cancer cells.
    Sachdev A; Matai I; Gopinath P
    Colloids Surf B Biointerfaces; 2016 May; 141():242-252. PubMed ID: 26854583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.
    Wu J; Tang C; Yin C
    Acta Biomater; 2017 Jan; 47():81-90. PubMed ID: 27729232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles.
    Pilapong C; Keereeta Y; Munkhetkorn S; Thongtem S; Thongtem T
    Colloids Surf B Biointerfaces; 2014 Jan; 113():249-53. PubMed ID: 24103503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles.
    Zhang T; Xiong H; Dahmani FZ; Sun L; Li Y; Yao L; Zhou J; Yao J
    Nanotechnology; 2015 Apr; 26(14):145101. PubMed ID: 25771790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyaluronic acid-modified multiwalled carbon nanotubes for targeted delivery of doxorubicin into cancer cells.
    Cao X; Tao L; Wen S; Hou W; Shi X
    Carbohydr Res; 2015 Mar; 405():70-7. PubMed ID: 25500334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin.
    Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X
    Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nanodroplets Engineered with Folate Carbon Dots for Enhanced Cancer Cell Uptake toward Theranostic Application.
    Kumawat A; Saini B; Ghoroi C
    ACS Appl Bio Mater; 2024 Aug; 7(8):5483-5495. PubMed ID: 39046462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A tumor environment responsive doxorubicin-loaded nanoparticle for targeted cancer therapy.
    Zhu Q; Jia L; Gao Z; Wang C; Jiang H; Zhang J; Dong L
    Mol Pharm; 2014 Oct; 11(10):3269-78. PubMed ID: 24735448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential release of autophagy inhibitor and chemotherapeutic drug with polymeric delivery system for oral squamous cell carcinoma therapy.
    Saiyin W; Wang D; Li L; Zhu L; Liu B; Sheng L; Li Y; Zhu B; Mao L; Li G; Zhu X
    Mol Pharm; 2014 May; 11(5):1662-75. PubMed ID: 24666011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.
    Zoli W; Ulivi P; Tesei A; Fabbri F; Rosetti M; Maltoni R; Giunchi DC; Ricotti L; Brigliadori G; Vannini I; Amadori D
    Breast Cancer Res; 2005; 7(5):R681-9. PubMed ID: 16168113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.